Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Mohammed LamordeKimberly K Scarsi

Abstract

Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa. This was a longitudinal intensive PK study in Ugandan pregnant women receiving nevirapine-based antiretroviral therapy. Participants underwent intensive 12-hour PK sampling during the second trimester (T2; n = 4), third trimester (T3; n = 15) and 6 weeks postpartum (PP; n = 15). HIV-1 RNA was performed within 2 weeks of each visit. Nevirapine C12 above 3000 ng/mL was classified as optimal based on the suggested value for therapeutic drug monitoring. The pharmacokinetics of nevirapine were influenced by pregnancy, demonstrated by a 20% reduction in the maximum concentration, minimum concentration (C12), and area under the curve between T3 and PP visits (P = 0.001, P = 0.011 and P = 0.005, respectively). Ten subjects (66.7%) had C12 values <3000 ng/mL during T3. Of these participants, 7 partcipant's C12 concentrations increased to >3000 ng/mL during the PP visit. HIV-1 RNA were <1000 copies per milliliter at T3 and <400 copies per milliliter at PP in all patients. Nevirapine exposure was reduced in Ugandan wo...Continue Reading

References

Feb 1, 1993·Antimicrobial Agents and Chemotherapy·S H CheesemanJ J Keirns
Dec 14, 2001·HIV Clinical Trials·E P AcostaUNKNOWN Pediatric AIDS Clinical Trials Group 386 Protocol Team
Jun 10, 2003·Clinical Pharmacokinetics·Theodora E M S de Vries-SluijsMarchina E van der Ende
Jun 2, 2004·Clinical Pharmacokinetics·Michael R SymeJeffrey A Keelan
Dec 1, 2004·Clinical Pharmacokinetics·Mark Mirochnick, Edmund Capparelli
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Rolf P G van HeeswijkD William Cameron
Sep 22, 2006·AIDS·Alice M StekJennifer S Read
Oct 26, 2006·British Journal of Clinical Pharmacology·Nils von HentigAnnette Haberl
Dec 13, 2006·Antimicrobial Agents and Chemotherapy·Jashvant D UnadkatRuth E Tuomala
Feb 19, 2008·The Journal of Antimicrobial Chemotherapy·Christoph WyenUNKNOWN German Competence Network for HIV/AIDS
Mar 28, 2008·HIV Medicine·E V CapparelliUNKNOWN PACTG P1022 Study Team
Mar 28, 2008·HIV Medicine·J F J B NellenJ M Prins
Nov 8, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Mark MirochnickUNKNOWN PACTG 1026s Study Team

❮ Previous
Next ❯

Citations

Sep 29, 2012·Clinical Pharmacokinetics·Kajal BuckoreelallJennifer R King
Nov 16, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Tim R CresseyUNKNOWN IMPAACT P1026s Team
Dec 2, 2011·HIV Medicine·A M StekM Mirochnick
Dec 5, 2013·Transactions of the Royal Society of Tropical Medicine and Hygiene·Bilaal S AhmedRobert E Ferris
Oct 5, 2014·Seminars in Perinatology·Yang ZhaoRaman Venkataramanan
Feb 12, 2015·Clinical Pharmacology and Therapeutics·A OlagunjuA Owen
Aug 25, 2015·Pharmacotherapy·Elise M GilbertMilena M McLaughlin
Jun 26, 2015·The Journal of Antimicrobial Chemotherapy·Adeniyi OlagunjuSaye Khoo
Apr 24, 2014·Scandinavian Journal of Infectious Diseases·Lars NavérKarin Pettersson
Aug 9, 2011·Thérapie·Patrice MuretUNKNOWN Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique
Sep 15, 2016·Expert Review of Clinical Pharmacology·Baralee PunyawudhoKiat Ruxrungtham
Nov 2, 2016·PLoS Medicine·Gali ParienteGideon Koren
Feb 27, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Anna H TranUNKNOWN IMPAACT P1026s Protocol Team
Jan 25, 2018·Infectious Diseases·Lars NavérKarin Pettersson
May 20, 2016·Pharmacogenetics and Genomics·Adeniyi OlagunjuAndrew Owen
Jun 28, 2020·Journal of Pharmacokinetics and Pharmacodynamics·Khaled Abduljalil, Raj K Singh Badhan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Acquired Immune Deficiency Syndromes : JAIDS
Mark MirochnickIMPAACT 1026s Study Team
Journal of Acquired Immune Deficiency Syndromes : JAIDS
Brookie M BestInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group 1026s Study Team
Journal of Acquired Immune Deficiency Syndromes : JAIDS
Serge SchneiderRobert Wennig
© 2021 Meta ULC. All rights reserved